Search details
1.
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Proc Natl Acad Sci U S A
; 107(29): 13075-80, 2010 Jul 20.
Article
in English
| MEDLINE | ID: mdl-20615965
2.
Alternative Complement Pathway Inhibition by Lampalizumab: Analysis of Data From Chroma and Spectri Phase III Clinical Trials.
Ophthalmol Sci
; 3(3): 100286, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37228694
3.
The Role of the Complement Pathway in Clinical Progression of Geographic Atrophy: Analysis of the Phase III Chroma and Spectri Trials.
Ophthalmol Sci
; 3(4): 100301, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37304044
4.
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
JAMA Neurol
; 79(11): 1113-1121, 2022 11 01.
Article
in English
| MEDLINE | ID: mdl-36121669
5.
Phase 1 Study of the Anti-HtrA1 Antibody-binding Fragment FHTR2163 in Geographic Atrophy Secondary to Age-related Macular Degeneration.
Am J Ophthalmol
; 232: 49-57, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34214452
6.
Preanalytical approaches to improve recovery of amyloid-ß peptides from CSF as measured by immunological or mass spectrometry-based assays.
Alzheimers Res Ther
; 10(1): 118, 2018 11 28.
Article
in English
| MEDLINE | ID: mdl-30486870
7.
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.
Neurology
; 90(21): e1889-e1897, 2018 05 22.
Article
in English
| MEDLINE | ID: mdl-29695589
8.
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Alzheimers Res Ther
; 10(1): 96, 2018 09 19.
Article
in English
| MEDLINE | ID: mdl-30231896
9.
Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration.
Sci Transl Med
; 9(395)2017 06 21.
Article
in English
| MEDLINE | ID: mdl-28637922
10.
Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.
Proteomics Clin Appl
; 9(7-8): 715-31, 2015 Aug.
Article
in English
| MEDLINE | ID: mdl-25676562
11.
Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics.
Mol Neurodegener
; 9: 22, 2014 Jun 06.
Article
in English
| MEDLINE | ID: mdl-24902845
12.
Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor.
Int Immunopharmacol
; 11(4): 475-9, 2011 Apr.
Article
in English
| MEDLINE | ID: mdl-21238622
13.
Identification of substrates of human protein-tyrosine phosphatase PTPN22.
J Biol Chem
; 281(16): 11002-10, 2006 Apr 21.
Article
in English
| MEDLINE | ID: mdl-16461343
14.
A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis.
Am J Hum Genet
; 75(2): 330-7, 2004 Aug.
Article
in English
| MEDLINE | ID: mdl-15208781
15.
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.
ChemMedChem
; 2(1): 58-61, 2007 Jan.
Article
in English
| MEDLINE | ID: mdl-17154430
Results
1 -
15
de 15
1
Next >
>>